Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me too. This is my buy and forget stock - though I will be adding thru first half of 2016. I often do forget I own it because its so quiet and likely will be for some time. Which is fine. It will be good to all of us eventually.
Thank you Citrati! Maybe the JP Morgan conference will give SYN a little nudge towards positive trend. I don't think they're participating - IDRA and PIRS are - but sometimes the positive response to the conference is infectious.
Thank you for keeping these boards alive with your ideas and for sharing your knowledge. You are one of the best and most patient teachers I've ever had Citrati! I hope your holidays are wonderful and the New Year brings wonderful things to you.
Good. Boards are so quiet today you must have felt ignored. Glad you have your answer.
Nice move. I plan to buy more on Mon or Tues - to ride the anticipated wave to 5. JP Morgan week (01/10-01/14) should support the climb.
You're welcome C. I hope they partner that dahm thing soon.
Hopefully by the end of this month.
I think Trimesta uncertainty is dragging SYN down like a lead weight. If they can partner it, we'd finally start seeing positive market reaction for other parts of the pipeline. Trimesta has been killing them since this team took over. Legacy drug from hell.
From Nov 15 presentation:
Anticipated Upcoming Milestones and Estimated Timeline
• December 2015 - Posters and symposium sponsorship at the XXI World Congress
on Parkinson’s Disease and Related Disorders in Milan, Italy
• Q4 2015 - Completion of CTH-200 bridging study
• Q4 2015 - Update on initial regulatory and clinical activities for European market
registration
• Q2 2016 - Top-line data from CTH-300 Phase 3 efficacy registration study
• Q4 2016 - Top-line data from CTH-301 Phase 3 safety registration study
• Q4 2016 - File New Drug Application with U.S. FDA
20
Financial Position*
Cash • CAD$109.5 million (USD $82.2 million)
• 12,144,622 common shares
• 3,260,954 warrants
• 973,017 options
• 16,348,593 Total (Fully Diluted)
Share Capital
*As at September 30, 2015
Cash numbers include USD$72.5 million public offering (less expenses) of 5,175,000 common shares
in the United States, which closed on June 23, 2015.
Stock symbols: NASDAQ (CYNA), TSX (CTH)
CYNA presentation next week:
World Congress of Parkinson’s Disease (WCPD)
December 6-9, 2015
Milan, Italy
C! Is it your birthday???? Have a happy one! And 50 more!
Morning everyone! $3.50 in premarket. Very nice!
$IDRA. Oh My God!!!
Just read the news with a 'well, well, well' and a hhhmmmmmm.....Nice background on all 3 hires. GSK sinking their hooks in deeper...Premarket loves the news too. 3.80 right now.
Agree fully Citrati! Of course, you knew that anyway. Thanks for TA!
I've been seeing your name everywhere lately! You're now in all 3 of my biggest holdings - SYN/IDRA/PIRS - or at least your highly enthusiastic followers are! Good luck and enjoy the great runs!
It's a very Adam Smith-like post. Great read. Thanks!
I'm with ya there - they could benefit by a little more enthusiasm in that department. Just one sign of life would be good!
agree wholeheartedly. And the market will to, I think.
Yup - hopefully they'll make a partnership announcement soon. That's the other piece people have been waiting for. UCLA has been incredible at raising funds so far. The MRI results will strengthen that ability. Donors such as MS Foundation, new partner and SYN - that is the mix I'm looking for to fund next stage.
The debates are starting and already heated about the trial results. Much ado about....trimesta and RRMS - when we know UCLA has chosen to aggressively pursue the cognition. If they never talk about RRMS again - I'm fine with that - even though the first year relapse support of trimesta is significant. That's nothing new - we have known that for some time now. Most importantly -they are well supported for positive results in cognition trial. That's where its at and that's where they should go. So RRMS results are debatable, but how anyone is debating the MRI results is truly beyond me. Granted, I am not schooled in MRI reading or interpretation, but the conclusions of those who are, those who examined the MRI results of this study, are clearly and firmly positive. I am relieved and happy. Doesn't matter if the market concludes the RRMS response wasn't robust enough. The MRI data is.
Yes. No one loses when they lock in some profits.
He did a GREAT job dissecting 004. Only detail that I could see missed was preclinical validation of ph dissolution range - which for me decreases risk of added ppi. It's an impressive write up.
Wow! My local Boston news station yesterday said Idera royalties with this deal have 1/2 billion potential.
they're supporting news flow lately. Supporting good run!
God. This is so sweet. All my baby biotechs flying today - but IDRA strongest by far with this solid long term news. (Pleased)sigh.
Depends. Does market like trimesta publication? Does syn announce good partnership deal soon after publication? Hopefully we'll spike nice and high with each of those events, close to 5 if we get both timed closely, and settle back to mid 3s as new low area which would be strong foundation for increase from 004 and 010 trial news. Thats my most hopeful scenario anyway. If we only get the publication bounce, I'm hoping we climb at least temporarily into the 4s. There is always the chance that the market will not like the publication. That means tomorrow might be our best chance to skim some profits from the prepub enthusiasm.
Great read - still have to watch the video but the text summary was pretty strong. I totally agree with the sentiment and think now is the time to be loading on gold. Good luck!
I am ready. Sold a lot last run and rebought. Trying to weigh actions re Monday. We'll probably run a bit more and then we'll have response to DrV's article Tuesday - which is a bit too binary an event for me. We still have time to get pummeled before another run up to 12/10 conference. If investors like her article - we'll have beautiful climb right into second week of Dec.
You're welcome!
The Lancet is a great journal. She has published there before. Doesn't look like we'll get the MRI results that the trimesta investors want so much though - at least that is my interpretation of this statement from the UCLA MS page:
"In our recently completed multicenter trial of estriol in women with MS where we found significant beneficial effects on relapses and cognition, we acquired brain MRI scans. These MRI scans now need to be assessed for which region of the brain estriol treatment had the greatest effect impact on halting gray matter atrophy and with correlation to improvement in each disability."
I do like this statement: "A trial focusing on whether estriol treatment can improve cognition in not only RRMS, but also in progressive MS is needed. We have begun that trial, and it is ongoing at 4 sites across the U.S. Based on our results in the relapse trial, we know that this new trial is on target with regard to its optimal design and outcomes. In this trial, estriol treatment can be added on to other standard of care MS treatments (not just Copaxone, but also interferons or the new orals) or estriol can be used in people on no other MS treatments. The treatment duration is one year, and the primary outcome is cognitive testing."
And this statement makes me consider the possibility that the write up may show more positives for cognition than for RRMS - which is not in anyway a negative in the long term. The cognition trial is structured and active and they have a ton of data to support positive outcome. But...since the published study goals were RRMS based, SYN could be pummeled. "An unfortunate likelihood is that a treatment that optimally preserves or repairs leg strength may be different from a treatment that optimally preserves or repairs cognitive ability, which may, in turn, be different from one for vision. It is unlikely that there will be a silver bullet treatment to repair all disabilities in MS. The “one size fits all” approach is untenable given the known differences in neurological pathways."
Who knows? I don't. Could be a seriously positive response or could give bashers opportunity to pummel. But if SYN is in for a beating, the pain will be short lived. The cognition trial currently underway is the most positive path for Trimesta. When it is done - there will likely be lots of celebrating and lots of green accounts.
http://neurology.ucla.edu/clinic/programs/multiple-sclerosis
I know. Makes ya laugh, doesn't it?
http://www.syntheticbiologics.com/2015-11-19-Synthetic-Biologics-to-Host-Microbiome-Clinical-Program-Seminar-in-New-York-City
Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City
-- Event to Highlight Company's Two Phase 2 Clinical Programs: Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection --
-- Scheduled for Thursday, December 10, 2015 --
Bought a little more today.
Thanks noretreat!
Thanks C.
Sincerely,
A heartbroken Seel
I know. Me too. I am stunned and hugely disappointed. Can't understand this move. Management is aware of his background and his earned and tainted reputation in the investing community. Many investors will pull out now. Company loses respect and investor trust with this move. We are not the only ones who will distance ourselves.
sh*t. This was my favorite phage play.
If I get a reply, I'll be sure to post it. I'm feeling really bad about this. Loved this company. Will hate to leave it.
Cripes. I don't know. He's not listed on their site and I can't find pr announcing him. I just emailed IR. Big concern. His being a director would mean me rethinking investment in this company.As much as I love APHB and see huge potential, I'd have to get out. He is the bad in bad management. Criminal - literally. Too big a trust issue for me.
good timing.